LALPATHLAB
Dr. Lal Path Labs
Each stock's 10,000-path forecast, rendered as light.
Dr. Lal Path Labs (LALPATHLAB) Stock Analysis & Case Study
Is LALPATHLAB a good buy? The data-driven verdict.
Dr. Lal Path Labs (LALPATHLAB) trades at ₹1,672,on the numbers it mixed signals, a Downstox Snapshot Score of 52/100.
On the numbers, Dr. Lal Path Labs (LALPATHLAB) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 53.1× earnings, ROE of 22.5%, a 59% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
LALPATHLAB fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is LALPATHLAB overvalued? LALPATHLAB P/E vs its sector
LALPATHLAB's P/E of 53.1× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.84% dividend yield is below the peer median of 1.65%.
LALPATHLAB share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of LALPATHLAB history (10%/yr drift, 28%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| LALPATHLAB 2027 | ₹1,223 | ₹1,738 | ₹2,486 | +6% |
| LALPATHLAB 2028 | ₹1,123 | ₹1,850 | ₹3,065 | +13% |
| LALPATHLAB 2029 | ₹1,055 | ₹1,966 | ₹3,663 | +20% |
| LALPATHLAB 2030 | ₹1,018 | ₹2,096 | ₹4,243 | +28% |
| LALPATHLAB 2031 | ₹1,001 | ₹2,234 | ₹4,867 | +37% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability LALPATHLAB goes up, or doubles?
The bull case for LALPATHLAB
- High return on equity (22.5%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- Strong ROCE (28.3%) shows the core business earns well above its cost of capital.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹3,663.
The bear case & risks
- A rich 53.1× P/E leaves a thin margin of safety if growth slows.
- A steep 11.2× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,055.
LALPATHLAB volatility & expected range, how bumpy is the ride?
Over the last 2.0 years LALPATHLAB compounded at 10%/year with annualized volatility of 28%. That volatility implies a 1-year 80% range of ₹1,223–₹2,486, the honest backbone behind any single price target.
LALPATHLAB price forecast, the full 60-month probability fan
LALPATHLAB price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds LALPATHLAB hits common targets within the simulated horizon?
Full multi-horizon detail on the LALPATHLAB price target & forecast page.
LALPATHLAB Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. LALPATHLAB scores 4/9,mixed financial health.
LALPATHLAB MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy LALPATHLAB with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 29.6% | 3.4× |
| ZerodhaCHEAPEST | 29.6% | 3.4× |
| DhanCHEAPEST | 29.6% | 3.4× |
Compare every broker on the LALPATHLAB MTF page.
LALPATHLAB vs peers,sector comparison
About Dr. Lal Path Labs: sector, index & market-cap context
Dr. Lal Path Labs (LALPATHLAB) is a mid-cap NSE-listed company, and a constituent of the Nifty 200 index group, with a market capitalisation of ₹28,023 Cr. See more Nifty 200 stocks.
How the LALPATHLAB Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Dr. Lal Path Labs's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
LALPATHLAB analysis, FAQs
Is Dr. Lal Path Labs (LALPATHLAB) a good buy?
On the numbers, Dr. Lal Path Labs (LALPATHLAB) mixed signals, a Downstox Snapshot Score of 52/100, weighing expensive at 53.1× earnings, ROE of 22.5%, a 59% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is LALPATHLAB overvalued or undervalued?
LALPATHLAB trades at 53.1× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the LALPATHLAB share price target for 2031?
LALPATHLAB's probability-weighted 2031 median target is ₹2,234, with an 80% range of ₹1,001–₹4,867 (10,000-path Monte-Carlo).
What is the probability LALPATHLAB doubles in 5 years?
The modelled probability of LALPATHLAB reaching ₹3,272 (2×) within 5 years is 27%.
What is the bull case for LALPATHLAB?
High return on equity (22.5%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. Strong ROCE (28.3%) shows the core business earns well above its cost of capital.
What are the risks in LALPATHLAB?
A rich 53.1× P/E leaves a thin margin of safety if growth slows. A steep 11.2× price-to-book means most of the value is intangible/expectations, not assets on the books.